Cambridge, UK, 14 November 2018. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, is pleased to announce that it has won the 2018 Lifestars “>£30m EU Private Finance Raise of the Year” Award.
Niall Martin, Chief Executive Officer of Artios said “It is fantastic to have won this award, voted for by a highly experienced judging panel, as well as participants from the life science community. Since its establishment in 2016, Artios has grown into a leading DNA Damage Response company with an exciting pipeline of assets, a world class R&D team with a strong track record in translating DNA repair projects from research to the clinic, and with an enviable cash position following two successful fundraises from high calibre investors.
“The past year has been transformative for Artios. The oversubscribed Series B fundraise, supported by high profile investors, is a strong endorsement of our world-leading development pipeline and reflects the opportunity for DDR to yield new breakthrough oncology products.”
Held at the Honourable Artillery Company in London, Artios was recipient of the “>£30m EU Private Finance Raise of the Year Award”, which recognises significant fund raising during 2018.
The Lifestars Awards brings together the global life science leaders, investors and deal makers, and is recognition of financial, strategic and clinical achievements in the industry over the last 12 months across Europe and the US. Lifestars is run in association with Jefferies held during the Jefferies Annual Healthcare Conference week in London, Europe’s largest healthcare investment banking conference.
For more information about Artios Pharma Ltd., please contact:
Artios Pharma Ltd.
Niall Martin, Chief Executive Officer
Nick Staples, Chief Business Officer
Tel: +44 (0)1223 804180
Media & IR Enquiries
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Tel: +44 (0) 203714 1789
Jill Steier/ John Grimaldi
Notes to Editors
About Artios Pharma Limited
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as the National Centre for Biomolecular Research at Masaryk University. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers. Backed by blue chip investors including: Arix Bioscience plc – Artios’ largest shareholder, SV Health Investors, M Ventures, IP Group plc, AbbVie Ventures, Andera Partners (formerly EdRIP), LSP (Life Science Partners), Pfizer Ventures and Novartis Venture Fund (NVF). Artios is based at the Babraham Research Campus in Cambridge, UK. www.artios.com